FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.

Novo Nordisk (NVO) stock is in focus as the firm gets FDA scrutiny over an Ozempic TV ad, the second warning it received for ...

This time, the FDA took issue with how the ad positioned Ozempic as superior to other GLP-1s, taking aim at small details from comedic devices to the color of shirts.

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has ...

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

Novo Nordisk (NVO) stock gained 3% after FDA issued warning letters to 30 telehealth firms over false claims about compounded semaglutide and tirzepatide drugs.

Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the Danish drugmaker said Monday.

Turning $100,000 into $1 million is a task few stocks can accomplish. Novo Nordisk doesn't seem likely to do so, especially ...

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50 ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

Shares of Novo Nordisk (NVO +5.12%) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker ...